Alltrna raises $109 million in a Series B financing to advance tRNA based therapies
CEO Michelle Werner explains the science behind how Alltrna is trying to harness transfer RNA to develop therapies for stop codon disease.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square